Every letter we have printed

What the single figure hides is the shape of what is left over. Ninety-eight per cent with one impurity at two is a different material from ninety-eight per cent with forty impurities at one twentieth each, and a buyer who cares about the second case is given no way to tell them apart.

Your table of what each method can see puts "only if resolved" against isoaspartate for RP-HPLC. That understates the difficulty. Resolving isoAsp from Asp routinely requires a method developed for the purpose, and on a generic gradient the two are frequently indistinguishable even at forty minutes.

A quiet objection to the whole framing. Blind purchasing treats suppliers as adversaries, which is a reasonable design assumption and a poor description of most of the trade. The programmes that have learned most have been the ones willing to ask questions as well as run tests.

Blind means the analyst does not know the origin. It does not mean the analyst does not know the expected answer, and for a common molecule at a common strength they will. That is a second blinding nobody attempts and it is not obvious it can be attempted.

Nobody has defined what custody means in a market where the buyer is an individual and the laboratory is on another continent. Importing the phrase from clinical practice without importing the institutions has produced a word with no local meaning.

The strongest blind design I have seen anywhere involved a third party holding the purchase record, the laboratory receiving numbered tubes and the mapping opened only after all results were in. It is not expensive. It is simply organisation, and organisation is what this market lacks.

A blind purchase can still be detected. Unusual delivery addresses, first-time customers ordering a single unit of an unusual line, payment methods that stand out — a supplier paying attention has several signals available, and none of them require anybody to behave badly.

Consider the incentive on the service. A badge is a recurring revenue line and an expiry rule reduces it. That is not corruption; it is ordinary commercial gravity, and reforms that run against gravity need somebody outside the arrangement to push them.

Colour is doing unearned work. Green reads as approved in every other context a shopper encounters, and a service that renders an ordinary numeric result in the vocabulary of a safety certification has borrowed authority it did not generate.

A suggestion for the services rather than for you: publish a price for a full package including the raw data files. I would pay it, my colleagues would pay it, and at present there is no line on any of the four price lists that lets me.

I would like to know how often a blind programme has been unable to complete a purchase — order cancelled, payment refused, nothing delivered. Those are results, they are never published, and they may be the most informative data any programme collects.

Consider the cost. A genuinely blind programme means buying material at retail, paying full freight, waiting in the ordinary queue and absorbing the whole expense with no cooperation from the seller. That is why so little of it happens, and the reason is arithmetic rather than principle.

Temperature during transit is a custody question and is treated as a logistics one. A sample that spent two days above ambient has been altered in transit, and no signature anywhere records that it happened.

Two services, two visual languages, no common meaning. A shield from one and a roundel from the other represent different underlying work, and the reader who has learned to recognise both has learned nothing about how they differ.

I read this twice, which is unusual, and the second reading was the useful one. Whatever the desk is doing with structure at the moment is working.

Where a supplier does test, ask for the limit against which the result was judged and who set it. A pass against an internally chosen limit is a statement about that limit as much as about the material.

Your explanation of endotoxin units is the clearest I have read outside a pharmacopoeia, and the unit is where most confusion starts. A limit expressed per milligram and a limit expressed per container are different constraints, and which one applies depends on how much material is used at once.

Sterility assurance is a property of a process, not a result of a test, and your article is one of the few popular treatments to say so. Testing twenty units from a batch of ten thousand has very limited power to detect low-level contamination. The confidence comes from the validation, the environmental monitoring and the media fills.

Where people give more than one reason, most analyses take the first mentioned, which is an ordering effect rather than a weighting. Asking respondents to rank would cost nothing and would change several published distributions.

Reasons are ranked in most reporting and the ranking is a function of the category list. Change the list and the ranking changes, which means the headline finding of most of these surveys is a property of their questionnaire.

Nobody discusses what maintenance does to the appetite for other interventions. Several accounts I have read describe a period in which nothing else was attempted because the current arrangement was working, and the cost of that pause only becomes visible later.

On archived certificates: ask for the previous three lots as well as the current one. A single document is a snapshot and tells you nothing about drift, and three consecutive ones will tell you more about the manufacturer than any individual figure on any of them.

The chain has a step nobody discusses: the person who selected the sample. If the seller chose which vial went to the laboratory, the result describes that vial and a selection decision, and the second half of that sentence never appears on the page.

Your anatomy of a certificate is the page I have pinned above the goods-in desk. The one field I would promote is the date of analysis as distinct from the date of issue. A certificate issued last month for a determination made two years ago is a true document about a lot that has since spent two years somewhere.

Units are quietly inconsistent across this trade. Water content by weight and water content by the Karl Fischer determination are usually the same thing and occasionally are not, and the abbreviation on the page does not distinguish them.

Reading this issue end to end, the thing that struck me is how often the answer is that nobody has looked. It is a depressing finding and it is plainly the true one.

What I would like to see published is simply the proportion of suppliers who offer the test as a paid extra. It is a fact somebody could establish in a fortnight of correspondence, and it would tell readers where the market actually stands.

Bacteriostatic preparations inhibit growth and do nothing about material already present. The word bacteriostatic is doing reassurance work in this market that its actual meaning does not support.

The phrase dose-limiting has a precise meaning in trial design and a loose one everywhere else. In a protocol it names the point at which escalation stops; in general use it names discomfort. The two are frequently conflated in coverage of the same study.

In this market the dose is a calculation performed by the buyer from a concentration they inferred, which introduces a source of variation absent from any trial. Anything read across from the trial literature carries that additional uncertainty.

The central component acting through the brainstem is often left out of popular accounts, which then explain nausea entirely in terms of the stomach. Both routes contribute and they predict different things about how quickly the effect settles.

A small point of precision. You use "gastroparesis" in the tag list and then spend a paragraph saying it is not a synonym for drug-induced emptying delay. That is a slightly awkward position to hold.

The first-dose period accounts for a disproportionate share of reported events, and reporting a single study-wide incidence hides that structure entirely. A rate by week would be far more informative than a rate by trial.

The figures that circulate are cumulative incidence over a whole trial, and they are read as though they described how somebody feels in a given week. Those are very different quantities, and the second is much smaller than the first. Your table separating them is the most useful thing published on this in a while.

Leucine and isoleucine are the standing rebuke to anyone who calls a mass measurement a sequence confirmation. Identical formula, identical mass, different molecule, and no amount of resolving power will separate them without fragmenting the chain. The distinction is not academic for a receptor-binding sequence.

Please keep pressing on the difference between identity confirmed and mass consistent with. They are different claims, the second is what was measured, and the first is what gets printed. A document that used the honest phrasing would lose nothing and would tell a buyer exactly what they have.

Sixteen years in a peptide plant and I have never once been asked by a customer which ionisation source we used. I have been asked hundreds of times for a purity figure to one more decimal place.

Nothing in a chromatogram addresses aggregation, and size-exclusion is the obvious complement rather than another reversed-phase run. It is a different question, a different column and a different afternoon, and for a peptide that has been through a freeze-thaw cycle it is frequently the more informative one.

The cheapest orthogonal method is not a second column, it is a change of mobile-phase pH on the column already installed. Formic acid in place of trifluoroacetic acid alters selectivity substantially for basic sequences and costs one equilibration. It is not a full second principle, and it will still separate a co-eluting pair more often than not.

Sub-two-micron columns changed everything about what is practical for peptide separations, but I would push back on the statement that particle size gains are costless. The pressure limit of most commercial instruments is three hundred bar, and trying to force 1.7-micron particles at eight millilitres per minute on a 4.6-millimetre column will send you there quickly. Peak capacity is not free.